

Regulatory Announcement

Company Akers Biosciences, Inc.
TIDM AKR
Headline Director/PDMR Shareholding
Released 07:01 20-Dec-07

RNS Number:3400K
Akers Biosciences, Inc.
20 December 2007

20 December 2007

Akers Biosciences, Inc.

("ABI" or the "Company")

Directors Shareholding & Additional Listing

Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, point of care screening and testing products announces that several of its directors have purchased shares of the Company's common stock and a retiring executive has been issued warrants to purchase shares of the Company's common stock.

David Wilbraham, Chairman, has converted £9,000 of director's fees into 61,017 shares of common stock. Mr. Wilbraham's shareholdings currently total 929,017 common shares.

Edward Mulhare, non-executive director, has converted \$11,250 of director's fees into 37,790 shares of common stock. Mr. Mulhare's shareholdings currently total 900,940 shares.

Daniel Seckinger, M.D non-executive director has converted \$57,375 of director and consulting fees into 192,728 shares of common stock. Dr. Seckinger's shareholdings currently total 967,616 common shares.

Carl E. King, retiring president of the Company's Breath Alcohol Detection Division, has converted \$114,304 in commission due on sales into warrants to purchase 383,957 shares of common stock. The exercise price of such warrants will be \$.001 and shall vest immediately.

The exchange rate used in the transactions is £1.00 = \$2.0182

Application has been made to the London Stock Exchange for 291,535 New Ordinary Shares ("Shares"), which will rank pari passu with existing Ordinary Shares, to be admitted to trading, such admission expected to take place on 4 January 2008.

The number of Shares with voting rights in issue following this transaction is 66,384,104. Therefore the total number of voting rights in the Company is 66,384,104 which number may be used by shareholders

as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FSA's Disclosure and Transparency Rules.

Enquiries:

Thomas A. Nicolette, President
Akers Biosciences, Inc.
Tel. 001 856 848 8698

Alasdair Younie
Arbuthnot Securities
Tel. 020 7012 2000

This information is provided by RNS
The company news service from the London Stock Exchange

END